Gene Logic Expands International Operations - Establishes Staff in UK and Germany

Forms Gene Logic K.K. to Serve Japanese Market

19-Aug-2004

Gene Logic Inc. announced the expansion of its European and Asia Pacific operations. Gene Logic has added sales and support staff to its European office, Gene Logic Ltd., based in London, and also hired a business development representative who will be based in Germany. In addition, the Company has established Gene Logic K.K., a wholly owned subsidiary based in Japan, to provide marketing and customer support in Japan. These initiatives reflect the Company's commitment to its European and Japanese customers and its mission to be the most innovative drug development partner for the pharmaceutical industry.

The Company recently reported that 14 percent and 33 percent of its total revenue for the period ended June 30, 2004 resulted from pharmaceutical and biotechnology companies based in Europe and Asia Pacific, respectively. With nearly 50 percent of its revenue generated from non-U.S. based customers, the Company continues to broaden its international presence to better serve existing customers in their home markets and to expand its worldwide customer base. Gene Logic's customers in Europe include Aventis, Novartis, UCB, Boehringer Ingelheim, GlaxoSmithKline and Solvay, and in Asia Pacific include Daiichi, Fujisawa, Mitsubishi, Sankyo, Sumitomo, and Takeda.

Mark D. Gessler, chairman and CEO, Gene Logic, commented, "In establishing international 'customer-facing' staff and infrastructure, Gene Logic will be better able to provide local service to customers in the global marketplace. 'To be global and act local' requires us to be ready to respond to customer needs and offer solutions rapidly and effectively. These initiatives, in combination with our recent establishment of a new research team in Cambridge, Massachusetts, continue our strategy of broadening our services offered and companies served to become the service partner of choice for pharmaceutical and biotechnology companies worldwide."

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances